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The retroviral restriction factors, TRIM5α and TRIMCyp, consist of RING and B-box 2 domains separated by a coiled coil from carboxy-
terminal domains. These carboxy-terminal domains (the B30.2(SPRY) domain in TRIM5α and the cyclophilin A domain in TRIMCyp) recognize
the retroviral capsid. Here we show that some B-box 2 changes in TRIM5α, but not in TRIMCyp, resulted in decreased human immunodeficiency
virus (HIV-1) capsid binding. The phenotypic effects of these B-box 2 changes on the restriction of retroviral infection depended on the potency of
restriction and the affinity of the TRIM5α interaction with the viral capsid, two properties specified by the B30.2(SPRY) domain. Thus, some
alterations in the TRIM5α B-box 2 domain apparently affect the orientation or conformation of the B30.2(SPRY) domain, influencing capsid
recognition.
© 2007 Elsevier Inc. All rights reserved.Keywords: Retrovirus; Restriction factor; TRIMCyp; Cyclophilin; Trimer; B-box 2; B30.2(SPRY); HIV-1; N-MLVIntroduction
Retroviruses encounter potent blocks to infection in certain
mammalian species. In many cases, the restriction is mediated
by dominant host factors, such as Fv1 (Best et al., 1996; Hartley
et al., 1970; Lilly, 1967; Lilly, 1970), APOBEC3G (Sheehy et
al., 2002) and TRIM5α (Stremlau et al., 2004). TRIM5α blocks
retroviral infection at an early post-entry step in a species-
specific manner. Rhesus monkey TRIM5α (TRIM5αrh)
potently blocks the infection of human immunodeficiency
virus-1 (HIV-1) and a range of other retroviruses; by contrast,
human TRIM5α (TRIM5αhu) modestly restricts HIV-1 infec-
tion and potently blocks infection by N-tropic murine leukemia
viruses (N-MLV) (Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al.,
2004). The mechanism by which TRIM5α blocks retroviral
infection has not been clearly defined. Previous studies
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doi:10.1016/j.virol.2007.04.022viral cores and accelerate the uncoating process (Li et al.,
2006b; Perron et al., 2007; Sebastian and Luban, 2005;
Stremlau et al., 2006), thus potentially interfering with the
orderly disassembly of the viral capsid (Forshey et al., 2002).
TRIM5α is a member of the large tripartite motif (TRIM)
protein family (Reymond et al., 2001). TRIM proteins contain
RING, B-box 2 and coiled-coil domains; many cytoplasmic
TRIM proteins, like TRIM5α, also contain a B30.2(SPRY)
domain (Meroni and Diez-Roux, 2005; Reymond et al., 2001).
The B30.2(SPRY) domain of TRIM5α determines viral
specificity and potency of restriction by modulating recognition
of the retroviral capsid (Stremlau et al., 2005; Yap et al., 2005;
Perez-Caballero et al., 2005a; Li et al., 2006b). For example, in
an in vitro binding assay, the B30.2(SPRY) domain was shown
to be the major determinant of the association of TRIM5αrh
with the assembled HIV-1 capsid-nucleocapsid (CA-NC)
complex (Li et al., 2006b; Stremlau et al., 2006).
The role of TRIM5α domains other than the B30.2(SPRY)
domain in antiretroviral activity has been investigated. The
RING finger domain is the signature of a class of E3 ubiquitin
ligases involved in proteasome-mediated protein degradation
(Meroni and Diez-Roux, 2005). Indeed, some TRIM proteins
Fig. 1. TRIM5 and TRIMCyp constructs. The human and rhesus monkey
TRIM5α proteins, TRIM5αhu and TRIM5αrh chimeric proteins, and the owl
monkey TRIMCyp protein are depicted. A chimeric rh5RBCC-Cyp protein in
which the amino-terminal portion of TRIM5αrh was fused with the cyclophilin
A domain of owl monkey TRIMCyp was also studied. The changes introduced
into the B-box 2 domain of the proteins to create the Cluster I-A and II-A
mutants are shown. The carboxy-terminal HA tag is shown.
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their target proteins with ubiquitin (Dupont et al., 2005; Horn et
al., 2004; Meroni and Diez-Roux, 2005; Trockenbacher et al.,
2001; Xu et al., 2003). However, deletion of the TRIM5α RING
domain only partially attenuated antiviral activity (Javanbakht
et al., 2005; Perez-Caballero et al., 2005a; Stremlau et al.,
2004). Moreover, TRIM5α-mediated restriction activity was
not affected by modulation of E1 ubiquitin ligase activity in a
temperature-dependent cell line (Perez-Caballero et al., 2005b).
Finally, proteasome inhibitors did not impair the restriction
activity of TRIM5α (Perez-Caballero et al., 2005b; Stremlau et
al., 2006; Anderson et al., 2006; Wu et al., 2006). Proteasome
inhibitors can rescue viral reverse transcription from the
TRIM5α-mediated restriction, but the mechanistic basis for
this phenomenon is unknown (Anderson et al., 2006; Wu et al.,
2006). The B-box 2 domain plays an important but poorly
understood role in the function of TRIM proteins (Meroni and
Diez-Roux, 2005; Reymond et al., 2001). Deletion of the B-box
2 domain of TRIM5α eliminated its antiretroviral activities
(Javanbakht et al., 2005; Perez-Caballero et al., 2005a). It has
been suggested that the RING and B-box 2 domains may
specify an “effector” function, either by recruiting an additional
co-factor or by participating in particular types of self-
association (Diaz-Griffero et al., 2006b; Perez-Caballero et
al., 2005a; Stremlau et al., 2006). The coiled-coil domain is
known to be essential for both homomultimerization and
heteromultimerization of many TRIM proteins (Cao et al.,
1997; Javanbakht et al., 2006; Mische et al., 2005; Perez-
Caballero et al., 2005a; Reymond et al., 2001). TRIM5α
trimerization, which depends on the coiled coil and the L2
linker region connecting the coiled-coil and B30.2 domains,
contributes greatly to the avidity for the retroviral capsid and the
restriction of viral infection (Javanbakht et al., 2006).
In this study, we altered a combination of residues in the B-
box 2 domain of wild-type human and rhesus monkey TRIM5α,
as well as chimeric and mutant TRIM5α proteins, and examined
the effects of these changes on antiretroviral activity against
human immunodeficiency virus-1 (HIV-1), N-tropic Moloney
leukemia virus (N-MLV) and simian immunodeficiency virus
(SIVmac). The results show that, depending on the restriction
potency of the parental proteins, a property determined by the
B30.2(SPRY) domain, the same alterations of the B-box 2
domain can confer different phenotypes on retrovirus restric-
tion. Moreover, the B-box 2 alterations used in this study
dramatically affected the association of the TRIM5α proteins
with in vitro assembled HIV-1 CA-NC complexes, suggesting a
functional interplay between the TRIM5α B-box 2 and the
B30.2(SPRY) domains.
Results
Differential effects of TRIM5α B-box 2 changes on HIV-1 and
N-MLV restriction
Despite 87% sequence identity, rhesus monkey TRIM5α
(TRIM5αrh) and human TRIM5α (TRIM5αhu) exhibit differ-
ences in the spectrum of restricted retroviruses due to divergencein the B30.2 domains (Perez-Caballero et al., 2005a; Perron et
al., 2006; Stremlau et al., 2005; Yap et al., 2005). TRIM5αrh
more potently restricts HIV-1 infection than TRIM5αhu, whereas
TRIM5αhu more potently restricts the infection of N-MLV
(Hatziioannou et al., 2004; Keckesova et al., 2004; Perron et al.,
2004; Stremlau et al., 2004; Yap et al., 2004). In a previous study,
we generated two B-box 2 mutants of TRIM5αrh, each with a
few amino acid residues changed to that seen in a relatively
distant TRIM protein relative, TRIM21 (Li et al., 2006a). The
TRIM21 B-box 2 domain, in contrast to B-box 2 domains of
close TRIM5 relatives like TRIM6 or TRIM34, does not
effectively substitute for that of TRIM5αrh (Li et al., 2006a).
Mutant Cluster I-A exhibits the following changes: Q109E,
E110K, V114A, I115L and L118V; Mutant Cluster II-A exhibits
the following changes: E120A, R121Q, Q123R and E124K (Fig.
1). Thewild-type andmutant TRIM5αrh proteins were expressed
in HeLa cells (Fig. 2A). Both B-box 2 mutants restricted HIV-1
infection nearly as efficiently as the wild-type TRIM5αrh protein
(Fig. 2B). However, no anti-N-MLV activity was detected for
either of the mutants. In fact, N-MLV infected cells expressing
the Cluster I-A and Cluster II-A TRIM5αrh mutants more
efficiently than cells transduced with the control LPCX vector;
these mutants may exert dominant-negative effects on the
TRIM5αhu protein endogenously expressed in the HeLa cells.
Thus, the B-box 2 changes confer different phenotypes with
respect to the anti-HIV-1 and the anti-N-MLVactivities of rhesus
monkey TRIM5α.
To investigate the phenotypes of the B-box 2 mutants in the
context of more potent restriction against N-MLV infection, the
same changes were introduced into TRIM5αhu. Interestingly,
both TRIM5αhu mutants retained anti-N-MLV activity, but lost
the weak restricting activity against HIV-1 associated with wild-
type TRIM5αhu (Fig. 2B). These results demonstrate that
changes in the B-box 2 domain of TRIM5α can affect both
HIV-1 and N-MLV restriction. Apparently, if the parental
TRIM5α is a potent restrictor of a specific virus, then the
restriction activity directed against that virus can better tolerate
the changes introduced into the B-box 2 domain.
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by the B30.2(SPRY) domain
The determinants of species-specific differences in the
potency of TRIM5α-mediated restriction to HIV-1 and N-
MLV largely reside in the B30.2(SPRY) domain (Perez-
Caballero et al., 2005a; Perron et al., 2006; Stremlau et al.,
2005; Yap et al., 2005). The B30.2 domain from TRIM5αrh is
sufficient to confer potent anti-HIV-1 activity on TRIM5αhu,
whereas the B30.2 domain from TRIM5αhu further increases
the anti-N-MLV potency of TRIM5αrh (Perez-Caballero et al.,
2005a; Perron et al., 2006; Stremlau et al., 2005; Yap et al.,
2005). To examine whether the effects of the B-box 2 changes
on restriction are influenced by the B30.2(SPRY) domain, the
B-box 2 changes were introduced into two previously
established chimerae, TRIM5α R(H286-493) and TRIM5αFig. 2. Expression and antiretroviral activity of TRIM5α B-box 2 mutants. (A) The ex
expressing these proteins was determined by Western blotting comparable amounts
control for loading amount. Rh5, wild-type rhesus monkey TRIM5α; hu5, wild-type h
changes Q109E, E110K, V114A, I115L and L118V; the mutants labeled X(II) contai
where X represents the TRIM5 backbone (X=rh5, rhesus monkey TRIM5α; X=h
TRIM5α proteins described above on retroviral infection were assessed. HeLa cells s
transduced with the empty LPCX vector, were incubated with various amounts of H
Twenty microliters of the preparation of HIV-1-GFP used in these experiments c
correspond to ∼400 cpm reverse transcriptase units.H(R286-493) (Stremlau et al., 2005). TRIM5α R(H286-493) is
rhesus monkey TRIM5α containing a human TRIM5α B30.2
(SPRY) domain; TRIM5α H(R286-493) is human TRIM5α
with a rhesus monkey TRIM5α B30.2(SPRY) domain. The
residue numbering scheme is based on the human TRIM5α
sequence (Stremlau et al., 2005). The TRIM5α R(H286-493)
and H(R286-493) proteins, with wild-type or mutant B-box 2
domains, were expressed in HeLa cells (Fig. 3A). As expected
(Stremlau et al., 2005), HeLa cells overexpressing TRIM5α
R(H286-493) were more susceptible to HIV-1 infection than
cells expressing wild-type TRIM5αrh; however, compared to
cells transduced with the empty vector control (LPCX), the
TRIM5α R(H286-493)-expressing cells still exhibited a strong
restriction against HIV-1 infection (Fig. 3B). TRIM5α R(H286-
493) restricted N-MLV infection slightly more potently than
TRIM5αrh for the range of viral doses used. Introduction of thepression level of TRIM5α proteins with C-terminal HA tags in HeLa cells stably
of cell lysate with an anti-HA antibody. The blot was also probed for β-actin to
uman TRIM5α; the mutants labeled X(I) contain the Cluster I-A B-box 2 domain
n the Cluster II-A B-box 2 domain changes E120A, R121Q, Q123R and E124K,
u5, human TRIM5α) in which the changes were made. (B) The effects of the
tably expressing the wild-type and mutant TRIM proteins, or control HeLa cells
IV-1-GFP or N-MLV-GFP. Infected GFP-positive cells were counted by FACS.
orrespond to ∼3000 cpm reverse transcriptase units; 100 μl of N-MLV-GFP
Fig. 3. Expression and antiretroviral activity of TRIM5αrh-TRIM5αhu chimerae with B-box 2 changes. (A) Expression of the unmodified (wt) TRIM5α R(H286-
493) and H(R286-493) proteins and the Cluster I-A (I) and Cluster II-A (II) mutants was examined by Western blotting lysates from HeLa cells with an anti-HA
antibody (Roche). Lysates were Western blotted for β-actin as a control. Rh5=wild-type TRIM5αrh. (B) Infection with HIV-1-GFP and N-MLV-GFP of HeLa cell
lines stably expressing the indicated parental and mutant proteins. The results shown are typical of those obtained in two repeat experiments (rh5=TRIM5αrh;
hu=TRIM5αhu).
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493) protein resulted in restriction phenotypes different from
those seen in the TRIM5αrh background. The TRIM5αR(H286-
493)(I) and TRIM5α R(H286-493)(II) proteins did not detec-
tably block HIV-1 infection, whereas both mutants were almost
as potent as the parent TRIM5α R(H286-493) protein in res-
tricting N-MLV infection.
As previously reported (Stremlau et al., 2005), human
TRIM5α gained potent restriction activity against HIV-1 upon
acquiring the B30.2(SPRY) domain from TRIM5αrh (see
TRIM5α H(R286-493) in Fig. 3B); the N-MLV-blocking
activity of this chimera was slightly diminished compared to
that of TRIM5αhu. When the Cluster I-A and Cluster II-A
changes were introduced into TRIM5α H(R286-493), restric-
tion activity against N-MLV was completely lost, whereas the
anti-HIV-1 activities of these mutants were maintained (Fig.
3B). These results demonstrate that, in the presence of a B30.2
(SPRY) domain that specifies a strong restriction against a
certain target virus, the effects of the Cluster I-A and Cluster
II-A B-box 2 alterations can be functionally tolerated. On the
other hand, if the B30.2(SPRY) domain confers relatively
weak restricting ability to the TRIM5α protein, the two sets ofB-box 2 alterations completely eliminate detectable antiviral
activity.
Effects of B-box 2 alterations on the restriction activities of
human TRIM5α R332P
A single amino acid change (R332P) in the B30.2(SPRY)
domain of human TRIM5α is able to confer potent restricting
ability against both HIV-1 and SIVmac infection, even though
strong SIV-restricting activity is not a characteristic of either
TRIM5αrh or TRIM5αhu (Li et al., 2006b; Stremlau et al., 2005;
Yap et al., 2005). To examine how changes in the B-box 2
domain affect the multiple restriction activities of TRIM5αhu
R332P, the Cluster I-A and Cluster II-A alterations were
combined with the R332P change in human TRIM5α; the
antiviral activities of these TRIM5αhu variants were tested in
HeLa cells overexpressing these proteins (Fig. 4A). The two
sets of B-box 2 changes completely abolished the ability of the
proteins to block HIV-1 and SIVmac infection (Fig. 4B). Interes-
tingly, the Cluster II-A changes also greatly attenuated the
ability of TRIM5αhu R332P to restrict N-MLV infection,
whereas the TRIM5αhu R332P variant with the Cluster I-A
Fig. 4. Effects of B-box 2 domain changes on the antiretroviral activity of human TRIM5α R332P. (A) Expression of the mutant proteins in HeLa cells was analyzed by
Western blotting, as described in the Fig. 1 legend. Lysates were also blotted with an antibody against β-actin as a control (hu5 R332P=TRIM5αhu R332P). (B and C)
HeLa cells expressing the indicated proteins were incubated with HIV-1-GFP and SIVmac-GFP (B) and N-MLV-GFP (C), then analyzed for GFP expression by FACS.
Ten dose units of this preparation of SIVmac correspond to ∼3000 cpm reverse transcriptase units. The experiment was repeated twice with results similar to those
shown.
Fig. 5. Effects of the B-box 2 changes on the association of TRIM5 proteins with
assembled HIV-1 capsid complexes. Cell lysates of HeLa cells stably expressing
the C-terminally HA-tagged TRIM5 variants were used in the HIV-1 CA-NC
binding assay. The top and middle panels show the amounts of TRIM5 protein in
the input and pellet, respectively; the bottom panel shows the amount of HIV-1
CA-NC protein that was pelleted through the 70% sucrose cushion. None of the
TRIM5 protein variants were able to pellet through the 70% sucrose cushion in
the absence of added HIV-1 CA-NC complexes (data not shown) (hu5=human
TRIM5α; rh5=TRIM5αrh; wt=wild-type; I=Cluster I-A mutant; II=Cluster II-
A mutant).
238 X. Li et al. / Virology 366 (2007) 234–244changes efficiently blocked N-MLV infection (Fig. 4C). Thus,
many but not all of the antiviral activities of TRIM5αhu R332P
are sensitive to the B-box changes studied here.
The B-box 2 alterations decrease the capsid-binding abilities
of TRIM5α
TRIM5α variants from Old World monkeys specifically
associate with HIV-1 capsid complexes; this interaction depends
on the TRIM5α B30.2 domain (Stremlau et al., 2006). Human
and New World monkey TRIM5α proteins associate less
efficiently with HIV-1 capsid complexes, accounting for the
lack of HIV-1 restriction in cells of these species (Stremlau et al.,
2006; Li et al., 2006b). Because the B-box 2 changes in this
study affected TRIM5α restriction activity in a potency-
dependent manner determined by the B30.2 domain, the B-
box 2 changes might affect the capsid-binding abilities of
TRIM5α. To test this hypothesis, a previously established in
vitro HIV-1 CA-NC binding assay was employed (Li et al.,
2006b; Stremlau et al., 2006). As expected (Li et al., 2006b;
Stremlau et al., 2006), TRIM5αrh associated with the in vitro
assembled HIV-1 CA-NC complexes efficiently; TRIM5αhu
only weakly associated with the complexes (Fig. 5). TRIM5α H
(R286-493), which has a B30.2 domain from TRIM5αrh,
associated with the HIV-1 capsid complexes as efficiently as
the wild-type TRIM5αrh. Conversely, TRIM5α R(H286-493),with the B30.2 domain of TRIM5αhu, bound the HIV-1 capsid
complexes inefficiently. To our surprise, both sets of B-box 2
alterations dramatically reduced the binding capabilities of
TRIM5αrh, TRIM5α H(R286-493) and TRIM5αhu. The Cluster
I-A and Cluster II-A changes did not cause any perceptible
reduction in the binding of TRIM5α R(H286-493) to HIV-1
CA-NC complexes, possibly due to the low binding level seen
for the unmodified TRIM5α R(H286-493) protein and the
239X. Li et al. / Virology 366 (2007) 234–244sensitivity of this assay. These results indicate that the Cluster I-
A and Cluster II-A changes in the B-box 2 domain generally
affect the capsid-binding affinity of TRIM5α proteins.
The B-box 2 alterations do not affect trimerization and
subcellular localization of TRIM5α
On the linear sequence of TRIM5α the B-box 2 domain is
separated from the B30.2 domain by the coiled coil. One
possible explanation for how changes in the B-box 2 domain
could affect capsid binding is that the B-box 2 domain may be
required to correctly orient the coiled-coil domain for
trimerization, which in turn increases the avidity of TRIM5α
for retroviral capsids (Javanbakht et al., 2006). To evaluate this
possibility, TRIM5αrh and TRIM5α H(R286-493) and their
derived B-box 2 mutants were subjected to crosslinking with
glutaraldehyde. As shown in Fig. 6, the Cluster I-A and Cluster
II-A B-box 2 alterations do not significantly affect the ability of
TRIM5α proteins to trimerize.
Deletions or alterations of the TRIM5α RING and B-box 2
domains are in some cases associated with changes in the
subcellular localization of the mutant protein (Diaz-Griffero et
al., 2006a,b; Javanbakht et al., 2005; Reymond et al., 2001).
However, neither of the B-box 2 alterations studied here caused
redistribution of the TRIM5α proteins (Fig. 7). Within the limitsFig. 6. Oligomerization of TRIM5α protein variants. Lysates from HeLa cells
stably expressing the indicated TRIM5α proteins were crosslinked with
increasing concentrations of glutaraldehyde (0, 0.2, 0.4, 0.8 and 2.0 mM).
The crosslinked products were resolved by SDS-PAGE and visualized by
Western blotting with an anti-HA antibody. The position of the molecular weight
markers is indicated in the figure.of our ability to detect, the subcellular localization of the Cluster
I-A and Cluster II-A mutants exhibited cytoplasmic localiza-
tions similar to those of the parental TRIM5α variants.
Phenotype of B-box 2 changes in owl monkey TRIMCyp
A retrotransposition that occurred near the root of the owl
monkey lineage of New World monkeys resulted in a replace-
ment of the TRIM5 gene with TRIMCyp (Nisole et al., 2004;
Ribeiro et al., 2005; Sayah et al., 2004). The encoded TRIMCyp
protein consists of a fusion of the RING, B-box 2 and coiled coil
of TRIM5 with cyclophilin A. Because cyclophilin A interacts
with the capsid proteins of HIV-1 and at least a few other
retroviruses (Franke et al., 1994; Gamble et al., 1996; Lin and
Emerman, 2006; Yoo et al., 1997), TRIMCyp can restrict
infection by these viruses (Diaz-Griffero et al., 2006b; Nisole et
al., 2004; Sayah et al., 2004; Zhang et al., 2006). Because
cyclophilin A can bind with low affinity to monomeric HIV-1
capsid proteins (Yoo et al., 1997), the interaction of TRIMCyp
with retroviral capsids may be less sensitive to B-box 2 changes
than TRIM5α-capsid interaction. To test this hypothesis, the
abilities of wild-type TRIMCyp and B-box 2 Cluster I-A and
Cluster II-A mutants to bind HIV-1 CA-NC complexes were
compared. Fig. 8A shows that neither of the B-box 2 alterations
detectably affected the binding affinity of TRIMCyp for the
assembled HIV-1 capsid complexes.
The effect of the Cluster I-A and Cluster II-A changes in the
TRIMCyp B-box 2 domain on the ability to restrict HIV-1
infection was examined. The B-box 2 TRIMCyp mutants
blocked HIV-1 infection nearly as efficiently as wild-type
TRIMCyp (Fig. 8B). None of the TRIMCyp variants inhibited
N-MLV infection, as expected from the inability of cyclophilin
A to interact with MLV capsids (Braaten et al., 1996). We
conclude that the Cluster I-A and Cluster II-A alterations do not
appreciably affect TRIMCyp capsid interaction or antiviral
activity.
Phenotype of B-box 2 changes in the context of a
TRIM5-Cyp chimera
The different phenotypes associated with the Cluster I-A and
Cluster II-A B-box 2 changes in the contexts of TRIM5α and
TRIMCyp proteins could formally be attributed to the use of
cyclophilin A to bind the retroviral capsid or to the differences
between the TRIM domains of TRIM5α and TRIMCyp. To
distinguish these possibilities, we created and tested rhRBCC-
Cyp, in which the cyclophilin A domain from owl monkey
TRIMCyp replaces the B30.2(SPRY) domain of TRIM5αrh
(Fig. 1). The Cluster I-A and Cluster II-A B-box 2 changes were
introduced into the rh5RBCC-Cyp protein. These B-box 2
changes did not affect the ability of the rh5RBCC-Cyp protein
to bind HIV-1 CA-NC complexes (Fig. 9A). The abilities of the
rh5RBCC-Cyp Cluster I-A and Cluster II-A mutants to restrict
HIV-1 infection were as great as that of the unmodified
rh5RBCC-Cyp protein (Fig. 9B). The rh5RBCC-Cyp proteins
did not efficiently inhibit N-MLV infection (Fig. 9C). We
conclude that the Cluster I-A and Cluster II-A B-box 2 changes
Fig. 7. Localization of TRIM5α protein variants. HeLa cells stably expressing the indicated HA-tagged TRIM5α proteins (or the empty LPCX vector) were fixed and
permeabilized. Cells were stained with an anti-HA antibody followed by a secondary anti-rat IgG antibody conjugated with FITC. Stained cells were examined using a
confocal fluorescent microscope. The unmodified TRIM5α proteins (wt) are shown in the left column, and the Cluster I-A and Cluster II-A variants of each protein in
the middle and right columns, respectively.
240 X. Li et al. / Virology 366 (2007) 234–244do not affect capsid binding and HIV-1 restriction when the
capsid-binding moiety is cyclophilin A.
Discussion
Changes in the B-box 2 domains of TRIM5α and TRIMCyp
proteins have been shown to diminish or abolish antiretroviral
activity (Diaz-Griffero et al., 2006b; Javanbakht et al., 2005; Li
et al., 2006a; Perez-Caballero et al., 2005a). Some of these
changes do not appreciably decrease expression levels, alter
subcellular localization or affect the capsid-binding ability of
the TRIM5α/TRIMCyp proteins (Diaz-Griffero et al., 2006b;
Stremlau et al., 2006). These B-box 2 changes apparently
influence an “effector” function of TRIM5α/TRIMCyp that
operates after capsid binding. The nature of this effector
function is not known; it may be involved in the accelerated
uncoating of the retroviral capsid that is strongly correlated with
TRIM5α restriction of viral infection (Perron et al., 2007;
Stremlau et al., 2006).
Here we studied two clusters (Cluster I-A and Cluster II-A)
of TRIM5α B-box 2 changes involving residues that differbetween TRIM5 and the distant relative TRIM21. The TRIM21
B-box 2 domain very inefficiently substitutes for that of
TRIM5α, compared with the B-box 2 domains of the closer
TRIM5 relatives, TRIM6 and TRIM34 (Li et al., 2006a). On
models of the B-box 2 domain based upon the TRIM29 B-box 2
structure, most of the residues involved in the Cluster I-A and
Cluster II-A changes are predicted to be surface-exposed (data
not shown). A key observation of our studies is that the viral
restriction phenotypes of the Cluster I-A and Cluster II-A B-box
2 mutants of TRIM5α are conditional, influenced by both the
TRIM5α background and the restricted virus. The phenotypes
of the B-box 2 mutants are generally correlated with the potency
of the restriction against the particular viruses by the TRIM5α
parent with unmodified B-box 2 sequences. By analyzing
recombinant TRIM5α proteins, we show that the determinant of
the conditional B-box 2 phenotype is the TRIM5α B30.2
(SPRY) domain, which makes major contributions to capsid
binding (Stremlau et al., 2006). Direct analysis of binding to
HIV-1 capsid-nucleocapsid complexes revealed the surprising
finding that both Cluster I-A and Cluster II-A B-box changes
caused substantial reductions in capsid-binding affinity of
Fig. 8. Effects of B-box 2 changes on TRIMCyp function. (A) The indicated
TRIM5α and TRIMCyp variants were expressed stably in HeLa cells. Cell
lysates were incubated with HIV-1 CA-NC complexes and the mixtures were
layered onto a 70% sucrose cushion and centrifuged. The TRIM5α and
TRIMCyp proteins in the input and pellet were detected by Western blotting
with an anti-HA antibody. The CA-NC protein in the pellet was detected by
Western blotting with an anti-p24 antibody. (B and C) HeLa cells stably
expressing the indicated TRIM5α or TRIMCyp variants were exposed to the
indicated amounts of HIV-1-GFP (B) or N-MLV-GFP (C). GFP-positive cells
were counted. The results shown are those of a typical experiment; the
experiment was repeated with similar results.
Fig. 9. Effects of B-box 2 changes on the chimeric rh5RBCC-Cyp protein. (A)
The binding of the unmodified rh5RBCC-Cyp (wt) protein and the Cluster I-A
(I) and Cluster II-A (II) derivatives to HIV-1 CA-NC complexes was assessed on
70% sucrose cushions. TRIM5αrh (rh5) and TRIM5αhu (hu 5) were included as
controls. The steady-state expression level of the unmodified (wt) rh5RBCC-
Cyp protein was significantly lower than that of TRIM5αrh, and the Cluster I-A
and II-A derivatives of rh5RBCC-Cyp were expressed at approximately 5-fold
higher levels than that of the wt rh5RBCC-Cyp protein (data not shown). In the
binding assay, an attempt was made to adjust the amount of input lysate to offset
these different levels of expression. The TRIM5 proteins were detected by
Western blotting with an anti-HA antibody, and the CA-NC protein by an anti-
p24 antibody. (B and C) HeLa cells stably expressing the indicated proteins were
exposed to HIV-1-GFP (B) or N-MLV-GFP (C). GFP-positive cells were
counted. The results of typical experiments are shown.
241X. Li et al. / Virology 366 (2007) 234–244TRIM5α proteins. These results indicate that the decreases in
TRIM5α antiretroviral function associated with the Cluster I-A
and Cluster II-A changes, by definition, do not result from
disruption of an effector function. This conclusion is consistent
with the expectation that TRIM5α mutants with true effector
function defects will exhibit a restriction phenotype regardlessof the high affinity of TRIM5α for the capsid, as has been pre-
viously observed (Diaz-Griffero et al., 2006b; Stremlau et al.,
2006).
We considered several possible explanations for the
unexpected effect of the Cluster I-A and Cluster II-A B-box 2
changes on TRIM5α binding to the retroviral capsid:
1) Because TRIM5α trimerization contributes greatly to the
avidity for assembled HIV-1 capsid complexes (Javanbakht
242 X. Li et al. / Virology 366 (2007) 234–244et al., 2006) and because of the proximity of the B-box 2 and
coiled-coil domains, it is possible that the alterations
introduced into the B-box 2 domain affected TRIM5α trimer
formation or stability. However, we observed no differences
in trimerization between the TRIM5α proteins with and
without Cluster I-A and Cluster II-A changes.
2) The Cluster I-A and Cluster II-A changes could hypotheti-
cally disrupt B-box 2 contributions to capsid-binding affinity
that are mediated by B-box 2-capsid contacts or by B-box 2
interactions with cellular cofactors that promote higher
avidity. However, such models are incompatible with
previous observations that the TRIM5α B-box 2 domain
can be disrupted or deleted with no apparent decrease in
capsid-binding affinity (Stremlau et al., 2006).
3) The Cluster I-A and Cluster II-A B-box 2 changes might alter
capsid-binding avidity by influencing the orientation of the
B30.2(SPRY) domains. The available data are compatible
with this explanation. In particular, our observations with
TRIMCyp and rh5RBCC-Cyp mutants indicate the specifi-
city of the effects of these B-box 2 changes for TRIM5
proteins with B30.2(SPRY) domains. The Cluster I-A and
Cluster II-A B-box 2 changes exerted no detectable effect on
the ability of TRIMCyp or rh5RBCC-Cyp to bind HIV-1
capsid complexes. In the TRIMCyp and rh5RBCC-Cyp
proteins, the capsid-binding moiety of TRIM5α, the B30.2
(SPRY) domain, is replaced by cyclophilin A. Thus, the
disruptive effects of the Cluster I-A and Cluster II-A B-box 2
changes on HIV-1 capsid binding are apparently dependent
on the B30.2(SPRY) domains being the direct capsid-binding
entity; these disruptive effects are completely eliminated
when the capsid recognition function is mediated by the
cyclophilin A domain. These observations support a model in
which the B-box 2 and B30.2 domains are spatially related on
TRIM5α proteins. Presumably the spatial relationships and
potential packing contacts involving the B-box 2 and B30.2
(SPRY) domains on the TRIM5α trimer differ from those of
the B-box 2 and cyclophilin A domains on the TRIMCyp
trimer. Thus, in this model, the effects of Cluster I-A and
Cluster II-A B-box 2 changes on capsid binding are expected
to differ for TRIM5α and TRIMCyp proteins.
The observed effects of the Cluster I-A and Cluster II-A B-box
2 changes on capsid binding could be mediated by direct B-box 2–
B30.2(SPRY) contacts or by indirect alteration of subunit
relationships on the trimer. Precise understanding of these
relationships awaits a TRIM5α structure.
We note that the binding of the Cluster I-A B-box 2 mutants
to HIV-1 CA-NC complexes was generally very low, and did
not demonstrate an increase even for TRIM5α proteins
(TRIM5αrh (I) and TRIM5α H(R286-493) (I)) that exhibited
HIV-1-restricting ability. These observations suggest that, at
least for TRIM5α proteins like the Cluster I-A mutants whose
level of expression is low, the HIV-1 capsid-binding assay is not
sensitive enough to allow precise assessment of affinities that,
although low, can still influence biological phenotypes.
Although replacement of the TRIM5αhu B30.2(SPRY)
domain with the complete B30.2(SPRY) domain of TRIM5αrhreverted the HIV-1-restriction phenotype of the Cluster I-A and
Cluster II-A B-box 2 changes, the replacement of arginine 332
in the B30.2(SPRY) domain did not. This is consistent with
previous observations suggesting that, although the presence of
arginine at residue 332 is the major determinant of the poor anti-
HIV-1 potency of TRIM5αhu, its replacement is not sufficient to
achieve the same levels of HIV-1 capsid binding and restriction
as those of TRIM5αrh (Li et al., 2006b). Thus, TRIM5αhu
R332P has apparently gained sufficient affinity for the HIV-1
(and possibly SIVmac) capsids to allow restriction, but not
enough to counteract the influence of these particular B-box 2
alterations.
Further studies of TRIM5α and TRIMCyp may provide an
understanding of the structural basis of the functional inter-
domain relationships elucidated in this work.
Materials and methods
Plasmid construction
Mutations affecting the B-box 2 domain of the wild-type
human and rhesus monkey TRIM5α proteins and the TRIMCyp
proteins were introduced into pLPCX-TRIM5α and pLPCX-
TRIMCyp expression plasmids, respectively, using overlapping
PCR extension with primers carrying the corresponding nucleic
acid changes (Horton et al., 1989, 1993). The PCR-amplified
TRIM5 fragments were digested and cloned into the EcoRI and
ClaI sites of the pLPCX vector, as previously described (Strem-
lau et al., 2004). The chimeric constructs containing B-box 2
alterations were created by exchanging fragments generated by
BsmI and ClaI digestion of the above constructs and similarly
digested plasmids expressing TRIM5α R(H286-493), TRIM5α
H(R286-493), or TRIM5αhu R332P (Stremlau et al., 2005).
The rh5RBCC-Cyp protein contains residues 1–296 of
TRIM5αrh (MASGIL...FRELTDA
296) fused to the Cyp A
domain from owl monkey TRIMCyp. The junction of the
TRIM5αrh and TRIMCyp moieties in the rh5RBCC-Cyp has
the following sequence: ...FRELTDAQRYWDAAAWDLVAS-
AMVNPTV... All constructs contain C-terminal epitope tags
derived from influenza hemagglutinin (HA).
Creation of cells stably expressing TRIM proteins
Recombinant viruses were produced in 293FT cells (Invitro-
gen) by cotransfecting the pLPCX plasmids expressing TRIM
proteins with the pVPack-GP and pVPack-VSV-G packaging
plasmids (Stratagene). The pVPack-VSV-G plasmid encodes
the vesicular stomatitis virus (VSV) G envelope glycoprotein,
which allows efficient entry into a wide range of vertebrate cells
(Yee et al., 1994). The resulting virus particles were used to
transduce 2×105 HeLa cells in six-well plates. The transduced
HeLa cells were then selected in 1 μg/ml puromycin (Sigma).
Immunoblotting
HeLa cells stably expressing the transduced proteins were
lysed with phosphate-buffered saline (2.7 mM KCl, 1.5 mM
243X. Li et al. / Virology 366 (2007) 234–244KH2PO4, 138 mM NaCl, 8 mM Na2PO4) containing 1% NP40
and protease inhibitor cocktail (Roche). The lysates were
resolved by SDS-PAGE and Western blotted with horseradish
peroxidase (HRP)-conjugated anti-HA antibody (Roche) and
anti-β-actin antibody (Sigma).
Infection with viruses expressing GFP
Recombinant HIV-1, SIVmac, and N-MLV viruses expres-
sing green fluorescent protein (GFP) were made as previously
described (Perron et al., 2004; Stremlau et al., 2004). For
infection, 3×104 cells were seeded in 24-well plates and
incubated with the viruses for 60 h. Cells were then washed with
PBS, fixed with 3.7% formaldehyde and subjected to
fluorescence-activated cell sorting (FACS) analysis with a
FACScan (Becton Dickinson).
Crosslinking of TRIM proteins
Cell lysates prepared in 1% NP40/PBS/protease inhibitor
cocktail were incubated with varying concentrations (final
concentration: 0, 0.2, 0.4, 0.8 and 2.0 mM) of glutaraldehyde
(Sigma) at room temperature for 5 min, followed by the addition
of excess glycine to quench the reaction. The crosslinked lysates
were then subjected to SDS-PAGE and Western blotted with
HRP-conjugated anti-HA antibody (Roche).
Subcellular localization using immunofluorescence confocal
microscopy
HeLa cells stably expressing TRIM5α variants were cultured
on 8-well chamber slides. Twenty-four hours later, the cells
were fixed, permeabilized, and incubated with rat anti-HA 3F10
antibody (1:200, Roche) followed by secondary anti-rat IgG
conjugated with FITC (1:200, Santa Cruz). The processed cells
were analyzed using a confocal microscope (Nikon Eclipse
E800) with laser (Bio-Rad MRC 1024), and the images were
obtained using Bio-Rad Lasersharp 2000 software.
HIV-1 capsid-binding assay
Purification of recombinant HIV-1 CA-NC protein from
Escherichia coli was carried out as previously described
(Ganser et al., 1999). For a source of TRIM5 proteins, HeLa
cells stably expressing the TRIM5 variants were lysed by
freeze-thawing in hypotonic lysis buffer (10 mM Tris, pH 7.4,
1.5 mMMgCl2, 10 mMKCl, 0.5 mMDTT) containing protease
inhibitor cocktail (Roche). The lysates were then mixed with the
in vitro assembled HIV-1 CA-NC complexes and the binding
assay was carried out as previously described (Li et al., 2007; Li
et al., 2006b; Stremlau et al., 2006).
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